Study

A bacterial enzyme enhances both energy metabolism and health across the life span of C. elegans and mice

Liu Y, Hu Z, Duan D, Wu L, Zeng AP

PRECLINICAL ANIMAL STUDY 2026

Lipoic acid protein ligase A improved energy metabolism and health measures in C. elegans and mice without reducing maximum lifespan; no human data are available.

Summary Can a bacterial enzyme improve energy and health without shortening life? Show / hide ↓

Researchers genetically added LplA, a bacterial enzyme that helps control energy-related chemical reactions, to laboratory roundworms and mice. The animals showed better energy use and several signs of better health during life. Their maximum lifespan was not shortened. No people took part, so the results do not directly apply to humans.

What this means for you: This is not a supplement or treatment to buy or try. It is an early laboratory finding that needs safety and human studies before it could guide personal decisions.

early evidence
DesignPRECLINICAL ANIMAL STUDY
TierTier 3, Ingredient RCT (matching dose)
Year2026
JournalScience Advances
PublishedAug 21, 2026
Added to NO1GEVITYAug 23, 2026

Yang Liu and colleagues used bacterial lipoic acid protein ligase A, or LplA, as a defined molecular tool in C. elegans and mouse models. The stated goal was to raise energy metabolism while limiting the oxidative damage that can accompany higher metabolic flux. LplA expression improved energy metabolism and health across the lifespan in both model systems. The abstract states that maximum longevity was not compromised. It does not provide sample sizes, effect estimates, confidence intervals, or statistical values in the fetched PubMed record. The intervention is genetic and experimental. It is not an oral supplement and has not been tested in humans. The paper is relevant to longevity biology because it addresses a central trade-off: more energy turnover may help function but can increase oxidative stress. LplA is presented as a way to separate those effects. That claim remains preclinical. The phrase “intervene in human aging” describes a future possibility, not a demonstrated therapy. Translation would require delivery, dose, tissue targeting, immunogenicity, long-term tumor monitoring, and controlled human safety studies. This paper belongs in the mechanism and discovery tier, not in a consumer stack.

Our work not only transcends the long-standing paradox between energy metabolism and health life span but also provides a hereto unreported strategy to intervene in human aging.
Critic notes

C. elegans and mouse models only. The abstract provides no sample sizes or numerical effect estimates. LplA expression is not an established human intervention. The human-aging implication is a hypothesis that requires extensive safety and translation work.

Read the source

Cited by

1 encyclopedia entries reference this study.